solifenacin succinate
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder, Overactive
Conditions
Urinary Bladder, Overactive
Trial Timeline
Jun 1, 2004 → Apr 1, 2005
NCT ID
NCT00463541About solifenacin succinate
solifenacin succinate is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT00463541. Target conditions include Urinary Bladder, Overactive.
What happened to similar drugs?
20 of 20 similar drugs in Urinary Bladder, Overactive were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189800 | Phase 3 | Completed |
| NCT01981954 | Phase 3 | Completed |
| NCT01565694 | Phase 3 | Completed |
| NCT00909428 | Approved | Completed |
| NCT00337558 | Approved | Completed |
| NCT00463541 | Phase 3 | Completed |
| NCT00454740 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Bladder, Overactive